Akela reports total consolidated revenues of $4.2 million for three months ended March 31, 2014 Akela Pharma, Inc. Related StoriesNew antenna-like device makes breasts cancer surgery much easier for surgeonsNew RNA check of blood platelets can be used to identify location of cancerStudy shows uncommon HER2 missense mutations do not spread breasts cancer on their ownTotal consolidated revenues for the three months ended March 31, 2014 were $4.2 million, including $3.0 million of contract services, as compared to $2.6 million, including $1.6 million of contract services, for the same period during the previous year. Consolidated net income for the three months ended March 31, 2014 were $0.99 million, $0.03 per share, versus a lack of $0.32 million, per share, for the same intervals in 2010 2010.
Stefano Bertozzi – – performing executive director for INSP’s Middle for Evaluation, Research and Surveys – – stated that antiretrovirals are obtainable and economically accessible for nearly every person who has been confirmed to be living with HIV. He added, Nevertheless, if a patient does not adhere 95 percent or more to the rigorous drug therapy regimen, the medication seriously isn’t going to succeed. Regarding to Bertozzi, it is extremely difficult for HIV-positive people to adhere to their drug regimens without strong scientific and family members support. Continue reading “Akela reports total consolidated revenues of $4.”